Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial
| Autor: | Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, Moccetti T, Rossi MG, AnesiniA A, Allemano P, Reynaud SG, Fenoil R, Giannuzzi P, Corrà U, Gavazzi A, Grosu A, Volpi A, Jones KN, Lissi C, Turazza FM, Frigerio M, Febo O, Olmett F, Cirò A, Vincenzi A, Scelsi L, Campana C, Opasich C, Gualco A, Iannone MA, Cucchi G, Catania G, Tarantini L, Rigatelli G, Boni S, Carlon R, Sacchetta A, Borgese L, Sarto P, Milan S, Milan D, Roncon L, Carraro M, Rossi R, Carbonieri E, Valentini A, Brighetti G, Cantarelli A, Ferrari R, FuciliF A, Bonfiglioli A, Mariani PR, Martinelli S, Buccolieri M, Moretti L, Partemi L, Gregori G, Testa D, Pulignano G, Santini M, Varveri A, Aspromonte N, Staniscia D, Calgione E, Vetrano A, Pettinati G, Ciricugno S, Gualtieri MR, Villella M, Lauletta R, Tagliamonte E, Scozzafava A, Cassano S, Misuraca G, Caporale R, Musca G, Carpino C, Leonardi G, Ledda G, Di Tano G, Cirrincione V, Sanfilippo N, Enia F, Floresta M, Porcu M, Orrù P., PERRONE FILARDI, PASQUALE |
|---|---|
| Přispěvatelé: | Røsjø, H, Masson, S, Latini, R, Flyvbjerg, A, Milani, V, La Rovere, Mt, Revera, M, Mezzani, A, Tognoni, G, Tavazzi, L, Omland, T, Moccetti, T, Rossi, Mg, Anesinia, A, Allemano, P, Reynaud, Sg, Fenoil, R, Giannuzzi, P, Corrà, U, Gavazzi, A, Grosu, A, Volpi, A, Jones, Kn, Lissi, C, Turazza, Fm, Frigerio, M, Febo, O, Olmett, F, Cirò, A, Vincenzi, A, Scelsi, L, Campana, C, Opasich, C, Gualco, A, Iannone, Ma, Cucchi, G, Catania, G, Tarantini, L, Rigatelli, G, Boni, S, Carlon, R, Sacchetta, A, Borgese, L, Sarto, P, Milan, S, Milan, D, Roncon, L, Carraro, M, Rossi, R, Carbonieri, E, Valentini, A, Brighetti, G, Cantarelli, A, Ferrari, R, Fucilif, A, Bonfiglioli, A, Mariani, Pr, Martinelli, S, Buccolieri, M, Moretti, L, Partemi, L, Gregori, G, Testa, D, Pulignano, G, Santini, M, Varveri, A, Aspromonte, N, Staniscia, D, Calgione, E, Vetrano, A, PERRONE FILARDI, Pasquale, Pettinati, G, Ciricugno, S, Gualtieri, Mr, Villella, M, Lauletta, R, Tagliamonte, E, Scozzafava, A, Cassano, S, Misuraca, G, Caporale, R, Musca, G, Carpino, C, Leonardi, G, Ledda, G, Di Tano, G, Cirrincione, V, Sanfilippo, N, Enia, F, Floresta, M, Porcu, M, Orrù, P. |
| Rok vydání: | 2010 |
| Předmět: |
Male
endocrine system medicine.medical_specialty Randomization Renal function Gastroenterology law.invention Randomized controlled trial law Diabetes mellitus Internal medicine Humans Medicine Heart rate variability Rosuvastatin Aged Aged 80 and over Heart Failure biology business.industry Chromogranin A Middle Aged Prognosis medicine.disease Endocrinology Heart failure Chronic Disease biology.protein Female Cardiology and Cardiovascular Medicine business Biomarkers medicine.drug |
| Zdroj: | On behalf of the GISSI-HF Investigators, Denmark 2010, ' Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial ', European Journal of Heart Failure, vol. 12, no. 6, pp. 549-56 . https://doi.org/10.1093/eurjhf/hfq055 |
| ISSN: | 1388-9842 |
| DOI: | 10.1093/eurjhf/hfq055 |
| Popis: | Udgivelsesdato: 2010 AIMS: To assess the association between circulating levels of chromogranin A (CgA) and outcome in a large population of patients with chronic heart failure (HF). METHODS AND RESULTS: Plasma CgA levels were measured at randomization and after 3 months in 1233 patients (median age 68 years, 80% male) with chronic, stable HF from the GISSI-HF trial. Circulating CgA levels were associated with several established risk markers in HF, including increased age, diabetes, reduced renal function, and heart rate variability. During a median follow-up of 3.9 years, 333 patients (27%) died. By univariable analysis, plasma CgA levels at baseline were strongly associated with all-cause mortality during follow-up; 2nd vs. 1st tertile: HR 1.58 (1.17-2.11), P = 0.002; and 3rd vs. 1st tertile: HR 2.35 (1.78-3.10), P < 0.0001. After adjustment for established risk factors of mortality, this association was attenuated and no longer significant. Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin did not significantly change plasma CgA concentration over 3 months. CONCLUSION: Measurement of circulating CgA levels in patients with chronic, stable HF does not provide incremental prognostic information to that obtained from physical examination, routine biochemical analysis, and contemporary HF biomarkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|